A report from the Dana-Farber Cancer Institute documented a 22% pathological complete response with single-agent cisplatin in the neoadjuvant setting for 28 women with early stage triple-negative breast cancer; only 2 patients were known BRCA1 mutation carriers, though both achieved a complete response [70]. The gene discussed is BRCA1; the disease is triple-negative breast carcinoma.